您当前所在的位置:首页 > 产品中心 > 产品详细信息
331771-20-1 分子结构
点击图片或这里关闭

N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide

ChemBase编号:72511
分子式:C29H31N5O4
平均质量:513.58754
单一同位素质量:513.2376045
SMILES和InChIs

SMILES:
O1CCN(CC1)CCCOc1c(cc2c(c1)ncnc2Nc1ccc(cc1)NC(=O)c1ccccc1)OC
Canonical SMILES:
COc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(cc1)NC(=O)c1ccccc1
InChI:
InChI=1S/C29H31N5O4/c1-36-26-18-24-25(19-27(26)38-15-5-12-34-13-16-37-17-14-34)30-20-31-28(24)32-22-8-10-23(11-9-22)33-29(35)21-6-3-2-4-7-21/h2-4,6-11,18-20H,5,12-17H2,1H3,(H,33,35)(H,30,31,32)
InChIKey:
OGNYUTNQZVRGMN-UHFFFAOYSA-N

引用这个纪录

CBID:72511 http://www.chembase.cn/molecule-72511.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide
IUPAC传统名
N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide
别名
ZM-447439
N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide
ZM 447439
CAS号
331771-20-1
PubChem SID
162037436
PubChem CID
9914412

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
PubChem 9914412 external link

理论计算性质

理论计算性质

JChem
Acid pKa 12.41361  质子受体
质子供体 LogD (pH = 5.5) 2.71315 
LogD (pH = 7.4) 3.992676  Log P 4.0960917 
摩尔折射率 148.0191 cm3 极化性 56.95799 Å3
极化表面积 97.84 Å2 可自由旋转的化学键 10 
里宾斯基五规则 false 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO expand 查看数据来源
外观
Pale Yellow Solid expand 查看数据来源
熔点
117-120°C expand 查看数据来源
保存条件
-20°C expand 查看数据来源
Refrigerator expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
作用靶点
Aurora Kinase expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals TRC TRC
Selleck Chemicals -  S1103 external link
Research Area
Description Canccer
Biological Activity
Description ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively.
Targets Aurora A Aurora B
IC50 110 nM 130 nM [1]
In Vitro In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. [1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. [2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. [3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. [4]
In Vivo
Clinical Trials
Features ZM-447439 is an Aurora selective ATP-competitive inhibitor.
Protocol
Kinase Assay [1]
In vitro kinase assays Recombinant Aurora A and B are expressed as NH2-terminal His6-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl2, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of 33P with a BetaplateTM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.
Cell Assay [2]
Cell Lines BON, QGP-1 and MIP-101 cells
Concentrations 0-5 μM
Incubation Time 72 hours
Methods Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.
References
[1] Ditchfield C, et al. J Cell Biol. 2003, 161(2), 267-280.
[2] Georgieva I, et al. Neuroendocrinology. 2010, 91(2), 121-130.
[3] Teperek-Tkacz M, et al. Cell Cycle. 2010, 9(23), 4674-4687.
[4] Zhang L, et al. J Obstet Gynaecol Res. 2011, 37(6), 591-600.
Toronto Research Chemicals -  Z487000 external link
It is a potent and selective inhibitor of Aurora B kinase. Cells treated with ZM-447439 progress through interphase, enter mitosis and assemble bipolar spindles but chromosome alignment, segregation and cytokinesis all fail. It induces apoptosos in Hep2 c

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle